Attovia Therapeutics, Inc. Common Stock Morgan Stanley 24th Annual Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Right. Good morning, everyone. Welcome to this session of the Morgan Stanley Global Healthcare Conference. I'm Judah Frommer, one of the SMID Biotech analysts. We're very excited to have Tao Fu, President and CEO from Attovia with us. Let me just get through a quick disclosure tab before we get started. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. All right, with that out of the way, Attovia had an exciting IPO in August. Congrats to the team on that.
Thank you. Before we dive in, can maybe give the audience a quick intro with a bit of background on how the team came together and the company formation?
Sure. Well, Judah, thanks for having me here. It's a real pleasure. Attovia was founded just a little bit over a few years ago in June of 2023, and really with a simple thesis of trying to change the paradigm for immune-mediated disease treatment with our ATTOBODY platform-based biologics. We started with a small group of highly experienced drug developers and scientists with early backing from Frazier Life Sciences and venBio. And really there was two shared beliefs between the teams, our investors, that first, the ATTOBODY platform can really have the potential to deliver breakthrough efficacy for IMI treatment. And having a small and highly focused and integrated team can deliver exceptional speed. So that's what we have done over the last two years. We moved our lead program, ATTO-1310, from concept to clinical proof concept in patients.
We have built a sustainable pipeline of near development stage multi-specifics.
and also complete an upsized IPO. We are very proud of that speed and execution, but we also think it is very repeatable.
Right. It has been busy. I want to spend a little more time on the platform. Maybe just walk us through the capabilities of the platform, how candidates are screened and developed. What advantage does the ATTOBODY platform provide over other approaches to antibody or biologic development?
Yeah. The ATTOBODYs are a biparatopic modality.
which means it has two VHH or nanobody binding arms, and each of them binds to a separate epitope on the same protein target, and they're connected by a linker. Our proprietary linker technology basically enables each of the VHH arms to interact ultimately with the target.
ATTOBODY based therapeutics have several unique attributes which make them ideally suited for complex biologics. I can give you a few examples. The biparatopic binding hold give you ultra high affinity and often best in class potency. ATTO-1310, as an example, builds highly potent monospecific against IL-31 ligand. ATTOBODYs are highly modular, so they're like Lego pieces. They can be put together Right in multi-specific formats and retain potency against individual targets.
We can also easily extend the half-life. Great for building multi-specifics. Right.
We can also tune the affinity of our binders to create truly conditional and gate bispecific. We can use high affinity to target a specific cell type.
and then lower affinity to activate the effector function when the drug is in the tissue.
Right. So far, we have done over 15 campaigns, and we have 100% success rate against all the targets we selected.
Great. Like you said, this modular nature of the platform, the building blocks are nanobody pairs. So maybe talk about the rationale for using nanobody binders over other formats. What have we learned about nanobodies from other programs?
Yeah. Nanobodies are really validated commercially, right? There are multiple FDA-approved products. There are multiple products containing nanobodies in late-stage clinical development with success. So it is very validated. It is very small, and it is very flexible, highly engineerable, so it give us the binding domain- Right that's ideally for a biparatopic binder.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring